Sonova Holding AG

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CH0012549785
CHF
205.90
4.8 (2.39%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Sonova Holding AG stock-summary
stock-summary
Sonova Holding AG
Pharmaceuticals & Biotechnology
Sonova Holding AG is a Switzerland-based company operating in the healthcare sector. The Company, along with its subsidiaries, designs, develops, manufactures, distributes and services hearing systems for adults and children with hearing impairment. The Company is active in two operating segments: the Hearing instruments segment includes the companies that are active in the design, development, manufacture, distribution and service of hearing instruments and related products, and the Cochlear implants segment includes the companies that are active in the design, development, manufacture, distribution and service of hearing implants and related products. It operates worldwide and distributes its products in over 90 countries through its own distribution network and through independent distributors. Sonova Holding AG is the holding company of the Sonova Group and operates the wholly owned subsidiaries Comfort Audio GmbH and Hansaton Akustik GmbH.
Company Coordinates stock-summary
Company Details
Laubisruetistrasse 28 , STAEFA None : 8712
stock-summary
Tel: 41 58 928333341 58 9283344
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 3 Foreign Institutions (0.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Robert Spoerry
Non-Executive Independent Chairman of the Board
Dr. Beat Hess
Non-Executive Independent Vice Chairman of the Board
Dr. Lukas Braunschweiler
Non-Executive Director
Ms. Lynn Bleil
Non-Executive Independent Director
Dr. Michael Jacobi
Non-Executive Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CHF 12,021 Million ()

stock-summary
P/E

22.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

223.86%

stock-summary
Debt Equity

0.49

stock-summary
Return on Equity

23.75%

stock-summary
Price to Book

4.95